Protecting Patients from Deceptive Drug Ads Act
Protecting Patients from Deceptive Drug Ads Act
Plain Language Summary
# Protecting Patients from Deceptive Drug Ads Act - Summary **What It Does:** This bill would create penalties for false or misleading advertisements about prescription drugs on social media and telehealth platforms. It specifically targets posts by social media influencers and healthcare providers who are paid to promote drugs but don't clearly disclose important information like side effects, contraindications (who shouldn't take the drug), or effectiveness data. The bill would require the FDA to issue guidance on what counts as deceptive advertising and to publicly report enforcement actions against violators. **Who It Affects:** The bill primarily impacts social media influencers, healthcare providers, and telehealth companies that promote prescription drugs online. It also affects pharmaceutical manufacturers, who would be notified by the FDA if ads about their drugs lack required safety information.
Patients would be the intended beneficiaries, as the law aims to prevent them from making drug decisions based on incomplete or false information. **Key Provisions:** The bill establishes civil penalties for knowingly or recklessly making false drug claims on social media or telehealth platforms, or failing to include required safety disclosures. It requires additional reporting requirements for telehealth providers and gives the FDA oversight authority to issue guidance and publish enforcement actions. **Current Status:** The bill (S. 652) was introduced in the 119th Congress by Senator Richard Durbin (D-Illinois) and is currently in committee, meaning it has not yet been voted on by the full Senate.
CRS Official Summary
Protecting Patients from Deceptive Drug Ads ActThis bill establishes civil penalties for false or misleading communications about prescription drugs by certain entities on social media. It also requires additional disclosures and reporting relating to drug advertisements on social media or via telehealth.The bill’s civil penalties apply when social media influencers or health care providers make communications regarding prescription drugs, using social media platforms, from which they financially benefit that (1) are made knowingly or recklessly and are false or inaccurate, or (2) fail to include the brief summary information (i.e., side effects, contraindications, effectiveness) required in drug advertisements. The Food and Drug Administration (FDA) must issue guidance and publish notice of such enforcement actions. The FDA may notify drug manufacturers when such communications fail to include the brief summary information.The bill also requires telehealth providers (i.e., entities that use telecommunications to bring together patients and drug prescribers or dispensers) to include the brief summary information in prescription drug advertisements.Also, payments from drug manufacturers to health care providers or social media influencers, or from health care providers to influencers, for communications promoting prescription drugs must be reported in accordance with anti-kickback laws for federal health care programs.Additionally, the FDA may conduct market surveillance regarding prescription drug promotion on social media, including analyzing communications and establishing a task force with the Federal Trade Commission.
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130)